A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors

Journal of Clinical Oncology

Volumn 28, Issue 29, 2010, Pages 4513-4520

  Sweeney, Christopher J ^a   Chiorean, E Gabriela ^a   Verschraegen, Claire F ^a   Lee, Fa Chyi ^a   Jones, Suzanne ^a   Royce, Melanie ^a   Tye, Lesley ^a   Liau, Katherine F ^a   Bello, Akintunde ^a   Chao, Richard ^a   Burris, Howard A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; SUNITINIB;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BILE DUCT CARCINOMA; BLADDER CANCER; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; COLORECTAL CANCER; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; DYSPEPSIA; ESOPHAGUS CANCER; FATIGUE; FEMALE; HAND FOOT SYNDROME; HUMAN; KIDNEY CARCINOMA; LIVER CANCER; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MESOTHELIOMA; MUCOSA INFLAMMATION; NAUSEA; NEUROENDOCRINE TUMOR; NEUTROPENIA; OPEN STUDY; PAIN; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; SOLID TUMOR; STOMACH CANCER; THYROID CANCER; TONGUE TUMOR; TREATMENT DURATION; TREATMENT RESPONSE; UROGENITAL TRACT TUMOR; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; DEOXYCYTIDINE; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; FLUOROURACIL; HUMANS; INDOLES; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NAUSEA; NEOPLASMS; PYRROLES; TREATMENT OUTCOME; VOMITING; YOUNG ADULT;

EID: 79951889122     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.26.9696     Document Type: Article

References (33)

1. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al: Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23:3502-3508, 2005
2. Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550, 2006 (Pubitemid 44917502)
3. Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676, 2007
4. Figg WD, Folkman J (eds): Angiogenesis: An Integrative Approach From Science to Medicine. New York, NY, Springer, 2008
5. Abrams TJ, Lee LB, Murray LJ, et al: SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2:471-478, 2003
6. Mendel DB, Laird AD, Xin X, et al: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327-337, 2003
7. Murray LJ, Abrams TJ, Long KR, et al: SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 20:757-766, 2003 (Pubitemid 38019277)
8. Genentech USA: Xeloda prescribing information. http://www.xeloda.com/pdf/ patient-pi.pdf
9. Abrams TJ, Murray LJ, Pesenti E, et al: Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2:1011-1021, 2003
10. Burstein HJ, Elias AD, Rugo HS, et al: Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26:1810-1816, 2008
11. Demetri GD, van Oosterom AT, Garrett CR, et al: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 368:1329-1338, 2006 (Pubitemid 44528723)
12. Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124, 2007 (Pubitemid 46089672)
13. Venturini M, Paridaens R, Rossner D, et al: An open-label, multicenter study of outpatient capecitabine monotherapy in 631 patients with pretreated advanced breast cancer. Oncology 72:51-57, 2007 (Pubitemid 350249129)
14. Osako T, Ito Y, Takahashi S, et al: Intermittent capecitabine monotherapy with lower dose intensity in heavily pretreated patients with metastatic breast cancer. Tumori 93:129-132, 2007 (Pubitemid 46866701)
15. Reichardt P, Von Minckwitz G, Thuss-Patience PC, et al: Multicenter phase II study of oral capecitabine (Xeloda®) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 14:1227-1233, 2003 (Pubitemid 37039048)
16. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
17. Rowland M, Tozer TN: Clinical Pharmacokinetics: Concepts and Applications (ed 2). Philadelphia, PA, Lea and Febiger, 1989
18. Jain RK: Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 307:58-62, 2005
19. Haller DG, Cassidy J, Clarke SJ, et al: Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol 26:2118-2123, 2008
20. Fumoleau P, Largillier R, Clippe C, et al: Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer 40:536-542, 2004 (Pubitemid 38220770)
21. Miller KD, Chap LI, Holmes FA, et al: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23:792-799, 2005 (Pubitemid 46224178)
22. Cassidy J, Twelves C, Van Cutsem E, et al: First-line oral capecitabine therapy in metastatic colorectal cancer: A favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 13:566-575, 2002 (Pubitemid 34461140)
23. Motzer RJ, Rini BI, Bukowski RM, et al: Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295:2516-2524, 2006 (Pubitemid 43854967)
24. Talbot DC, Moiseyenko V, Van Belle S, et al: Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 86:1367-1372, 2002 (Pubitemid 34548055)
25. Lacouture ME, Wu S, Robert C, et al: Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 13:1001-1011, 2008
26. Gressett SM, Stanford BL, Hardwicke F: Management of hand-foot syndrome induced by capecitabine. J Oncol Pharm Pract 12:131-141, 2006 (Pubitemid 44696441)
27. Mackean M, Planting A, Twelves C, et al: Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol 16:2977-2985, 1998 (Pubitemid 28417417)
28. Faivre S, Delbaldo C, Vera K, et al: Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25-35, 2006 (Pubitemid 46630490)
29. Pfizer: SUTENT (sunitinib) prescribing information, 2009. http://www.pfizer.com/files/products/uspi-sutent.pdf
30. Reigner B, Blesch K, Weidekamm E: Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 40:85-104, 2001 (Pubitemid 32242792)
31. Peters GJ, van der Wilt CL, van Triest B, et al: Thymidylate synthase and drug resistance. Eur J Cancer 31A:1299-1305, 1995
32. Milano G, Etienne MC, Pierrefite V, et al: Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br J Cancer 79:627-630, 1999 (Pubitemid 29046246)
33. van Erp NP, Eechoute K, van der Veldt AA, et al: Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol 27:4406-4412, 2009